Who Optimizes SG&A Costs Better? Amgen Inc. or CymaBay Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Amgen Inc. and CymaBay Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Amgen's SG&A expenses have seen a steady increase, peaking at approximately $6.2 billion in 2023, reflecting a 31% rise from 2014. This growth indicates Amgen's expansive operational strategies and market reach.

Conversely, CymaBay Therapeutics, a smaller player, has shown a more dramatic increase in SG&A expenses, surging over 500% from 2014 to 2023. This sharp rise, culminating in $51.9 million in 2023, suggests aggressive scaling and investment in administrative capabilities. While Amgen's expenses are significantly higher, CymaBay's rapid growth in SG&A costs highlights its ambitious expansion efforts in the biotech sector.